socaltech.com
San Diego-based
ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $115M. The funding came from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sander
The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please
login in order to access this members-only content, or
socaltech.com
Los Angeles-based
Appia Bio, a biotech startup focused on developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, has launched from stealth mode, saying it has raised $52M in a Series A funding round. The funding was led by 8VC, and also included Two Sigma Ventures, Sherpa Healthcare Partners and Freeflow Ventures. The company said its technology was originally developed in the laboratory of Lili Yang, PhD, associate professor at University of California, Los Angeles (UCLA). Appia said that Francisco Gimenez, PhD, and David Moskowitz, PhD, of 8VC, both join the company s board, with David Baltimore, PhD, of the California Institute of Technology (Caltech) serving as Chairman. The company said the proceeds from the funding will go to support advancement of its therapy candidates.